Know Cancer

or
forgot password

Pharmacokinetics and Metabolism of [14C] BMS-275183 in Patients With Advanced Cancer


Phase 1
18 Years
N/A
Not Enrolling
Both
Cancer

Thank you

Trial Information

Pharmacokinetics and Metabolism of [14C] BMS-275183 in Patients With Advanced Cancer


Inclusion Criteria:



- Non-hematological malignancy that has progressed on standard therapy

- No more that 3 prior chemotherapies given for advanced cancer

- Adequate renal, hepatic and hematologic function

Exclusion Criteria:

- Uncontrolled or significant pulmonary or cardiovascular disease

- Active Brain metastases

- Inability to swallow capsules

- Serious uncontrolled medical disorder or active infection

Type of Study:

Interventional

Study Design:

Allocation: Non-Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

To assess the Pharmacokinetics, metabolism, and routes and extent of elimination of a single dose of [14C] BMS-275183 over a 10 day period.

Authority:

United States: Food and Drug Administration

Study ID:

CA165-017

NCT ID:

NCT00326131

Start Date:

April 2006

Completion Date:

Related Keywords:

  • Cancer

Name

Location

Local InstitutionAustin, Texas